Use of IL-31 monoclonal antibodies for treating pruritus
Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human IL-31. CDR regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein V H and V L domains are attached. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for inflammatory diseases. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides. The invention further provides the amino acid sequences of the variable regions of the monoclonal antibodies and use of these monoclonal antibody or antibody fragment in conjunction with an human IgG4 Fc molecule.
1. A method of reducing IL-31-induced pruritus in a human comprising administering to the human a therapeutically effective amount of a composition comprising a monoclonal antibody that specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2, and a pharmaceutically acceptable carrier;
wherein the monoclonal antibody is a humanized monoclonal antibody derived from the antibody produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6815;
wherein the monoclonal antibody comprises a human IgG4 heavy chain immunoglobulin constant domain having a Serine to Proline mutation at Kabat position 241;
wherein the monoclonal antibody is administered subcutaneously or intravenously to the human; and
wherein after administration the pruritus is reduced.
2. The method according to claim 1 , wherein the IL-31-induced pruritis is atopic dermatitis.
3. A method of treating atopic dermatitis in a human comprising administering to the human a therapeutically effective amount of a composition comprising a monoclonal antibody that specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2, and a pharmaceutically acceptable carrier;
wherein the monoclonal antibody is a humanized monoclonal antibody derived from the antibody produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6815;
wherein the monoclonal antibody comprises a human IgG4 heavy chain immunoglobulin constant domain having a Serine to Proline mutation at Kabat position 241; and
wherein the monoclonal antibody is administered subcutaneously or intravenously to the human.
4. A method of reducing IL-31-induced scratching in a human comprising administering to the human a therapeutically effective amount of a composition comprising a monoclonal antibody that specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2, and a pharmaceutically acceptable carrier;
wherein the monoclonal antibody is a humanized monoclonal antibody derived from the antibody produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6815;
wherein the monoclonal antibody comprises a human IgG4 heavy chain immunoglobulin constant domain having a Serine to Proline mutation at Kabat position 241;
wherein the monoclonal antibody is administered subcutaneously or intravenously to the human; and
wherein after administration the scratching is reduced.